Johnson & Johnson [JNJ] vs Medicus Pharma [MDPLD] Detailed Stock Comparison

Johnson & Johnson

NYSE
Loading...

Medicus Pharma Ltd.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Johnson & Johnson wins in 9 metrics, Medicus Pharma Ltd. wins in 2 metrics, with 1 ties. Johnson & Johnson appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Johnson & Johnson Medicus Pharma Ltd. Better
P/E Ratio (TTM) 20.49 -1.47 Johnson & Johnson
Price-to-Book Ratio 6.68 3.90 Medicus Pharma Ltd.
Debt-to-Equity Ratio 60.50 0.10 Medicus Pharma Ltd.
PEG Ratio 0.42 N/A N/A
EV/EBITDA 16.84 0.00 Tie
Profit Margin (TTM) 21.83% 0.00% Johnson & Johnson
Operating Margin (TTM) 26.72% 0.00% Johnson & Johnson
EBITDA Margin (TTM) 26.72% N/A N/A
Return on Equity 32.87% -841.91% Johnson & Johnson
Return on Assets (TTM) 13.46% -358.37% Johnson & Johnson
Free Cash Flow (TTM) $19.31B $-4.16M Johnson & Johnson
Dividend Yield 2.09% N/A N/A
1-Year Return 53.32% N/A N/A
Price-to-Sales Ratio (TTM) 5.66 N/A N/A
Enterprise Value $574.25B $0 Johnson & Johnson
EV/Revenue Ratio 5.96 N/A N/A
Gross Profit Margin (TTM) 67.56% N/A N/A
Revenue per Share (TTM) $40 $0 Johnson & Johnson
Earnings per Share (Diluted) $11.04 $-2.54 Johnson & Johnson
Beta (Stock Volatility) 0.33 N/A N/A
Short % of Float 1.03% N/A N/A

Johnson & Johnson vs Medicus Pharma Ltd. Stock Performance Analysis

Loading Price Chart...

JNJ
MDPLD

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Johnson & Johnson-2.16%1.51%3.95%-3.10%10.03%13.65%
Medicus Pharma Ltd.1.78%0.00%0.00%0.00%0.00%0.00%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Johnson & Johnson53.32%46.67%48.70%108.58%263.36%290.52%
Medicus Pharma Ltd.N/AN/AN/AN/AN/AN/A

Performance & Financial Health Analysis: Johnson & Johnson vs Medicus Pharma Ltd.

MetricJNJMDPLD
Market Information
Market Cap i$555.84BN/A
Market Cap CategoryMega capN/A
10 Day Avg. Volume i8,370,56620,091
90 Day Avg. Volume i7,752,96536,712
Last Close$235.66$2.86
52 Week Range$149.04 - $251.71$1.80 - $6.00
% from 52W High-6.38%-52.33%
All-Time High$251.71 (Mar 02, 2026)$3.00 (Jan 24, 2025)
% from All-Time High-6.38%-4.67%
Growth Metrics
Quarterly Revenue Growth0.10%N/A
Quarterly Earnings Growth-0.52%N/A
Financial Health
Profit Margin (TTM) i0.22%0.00%
Operating Margin (TTM) i0.27%0.00%
Return on Equity (TTM) i0.33%-8.42%
Debt to Equity (MRQ) i60.500.10
Cash & Liquidity
Book Value per Share (MRQ)$33.87$0.73
Cash per Share (MRQ)$8.34N/A
Operating Cash Flow (TTM) i$22.21B$-4,987,008
Levered Free Cash Flow (TTM) i$43.47B$-6,784,140
Dividends
Last 12-Month Dividend Yield i2.09%N/A
Last 12-Month Dividend i$5.20N/A

Valuation & Enterprise Metrics Analysis: Johnson & Johnson vs Medicus Pharma Ltd.

MetricJNJ (Apr 24, 2026)MDPLD (Mar 31, 2025)
Price Ratios
P/E Ratio (TTM) i20.49-1.47
Forward P/E i17.80N/A
PEG Ratio i0.42N/A
Price to Sales (TTM) i5.66N/A
Price to Book (MRQ) i6.683.90
Market Capitalization
Market Capitalization i$555.84B$22.45M
Enterprise Value i$574.25B$0
Enterprise Value Metrics
Enterprise to Revenue i5.96N/A
Enterprise to EBITDA i16.840.00
Risk & Other Metrics
Beta i0.33N/A
Book Value per Share (MRQ) i$33.87$0.73

Financial Statements Comparison: Johnson & Johnson vs Medicus Pharma Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricJNJ (2025)MDPLD (2023)
Revenue/Sales i94.19B0
Cost of Goods Sold i30.26BN/A
COGS % of Revenue i32.1%-
Gross Profit i63.94BN/A
Gross Margin i67.9%-
Research & Development i14.67B193,578
Operating Income (EBIT) i25.60B-3.01M
Operating Margin i27.2%-
EBITDA i35.16B-6.72M
EBITDA Margin i37.3%-
Pre-Tax Income i32.58B-6.78M
Pre-Tax Income % of Revenue i34.6%-
Income Tax i5.78BN/A
Income Tax % of Revenue i6.1%-
Net Income (Profit) i26.80B-6.78M
Profit Margin i28.5%-

Balance Sheet & Liquidity Metrics

MetricJNJ (2025)MDPLD (2023)
Cash & Equivalents i19.71B1.72M
Total Current Assets i55.62B1.89M
Total Current Assets % of Revenue i59.1%-
Total Current Liabilities i54.13B1.09M
Total Current Liabilities % of Revenue i57.5%-
Long-Term Debt i39.44BN/A
Long-Term Debt % of Revenue i41.9%-
Total Shareholders Equity i81.54B805,800
Retained Earnings iN/A-19.18M
Retained Earnings % of Revenue i0.0%-
Property, Plant & Equipment i0N/A

Cash Flow Statement Comparison

MetricJNJ (2025)MDPLD (2023)
Operating Cash Flow i22.21B-4.99M
Operating Cash Flow % of Revenue i23.6%-
Capital Expenditures i-4.83BN/A
Free Cash Flow i19.31B-4.16M
FCF Margin i20.5%-
Debt Repayment i-14.09BN/A
Common Stock Repurchase i-5.95BN/A

Short Interest & Institutional Ownership Analysis

MetricJNJMDPLD
Shares Short i22.27MN/A
Short Ratio i2.90N/A
Short % of Float i1.03%N/A
Shares Outstanding i2.41B8.08M
Float Shares i2.41BN/A
% Held by Insiders i0.06%55.81%
% Held by Institutions i75.84%0.00%
% Held by Public i24.10%44.19%

Dividend Analysis & Yield Comparison: Johnson & Johnson vs Medicus Pharma Ltd.

MetricJNJMDPLD
Last 12-Month Dividend i$5.20N/A
Last 12-Month Dividend Yield i2.09%N/A
3-Year Avg Annual Dividend i$4.97N/A
3-Year Avg Dividend Yield i0.74%N/A
3-Year Total Dividends i$14.92N/A
Ex-Dividend DateFeb 24, 2026N/A